Keros has lined up 2026 catalysts centered on rinvatercept, including a Q2 2026 Phase II start in Duchenne muscular dystrophy (DMD) and regulatory plans for ALS. The company is shifting from planning into execution, creating near-term binary milestones that could re-rate the stock if the trial start and regulatory interactions proceed as scheduled. Monitor timing, enrollment risk, and upcoming corporate updates for potential stock-moving news.
Keros has lined up 2026 catalysts centered on rinvatercept, including a Q2 2026 Phase II start in Duchenne muscular dystrophy (DMD) and regulatory plans for ALS. The company is shifting from planning into execution, creating near-term binary milestones that could re-rate the stock if the trial start and regulatory interactions proceed as scheduled. Monitor timing, enrollment risk, and upcoming corporate updates for potential stock-moving news.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
